3 Bethesda MetroCenter
Bethesda, MD 20814
Phone: (001) 301 525 5262
A recent statistical analysis (Swinney DC, Anthony J (July 2011). “How were new medicines discovered?”. Nat Rev Drug Discov) reveals that a disproportionate number of first-in-class drugs with novel mechanisms of action come from phenotypic screening.
High Content Screening is a priority at CYTOO. Our cell-based assays combine robustness (low CV and high Z’ due to morphology standardization), multiplexed visual read-outs (static and dynamic), and throughput. All the assays we develop are 96-well compatible, while the 384 format is coming out soon.
There are several reasons why CYTOO is one of the leading phenotypic screening and High Content Screening company in the world:
And on top of that, our 3D spheroid cellular model OncoSpheres™ has a size interwell CV below 5%: although it is a 500um diameter spheroid, high-throughput image acquisition and image read-out multiplexing has been made possible!
Why don’t you let us develop and screen your favorite cell-based assay? Contact us now.